Use of PAK inhibitor for the treatment of a joint disease

US7364887B2 · kind B2 · utility

Assignee

• Sanofi-Aventis Deutschland GMBH · DE

Inventors

• Sebastian Barradeau · Paris, FR
• Eckart Bartnik · Hochheim, DE
• Joerg Czech · Marburg, DE
• Andreas Klatt
• Ekkehard Leberer · Germering, DE
• Thomas Leeuw · Greifenberg, DE

Key dates

• Filing date: Jul 16, 2004
• Grant date: Apr 29, 2008
• Expiry date: Apr 24, 2025

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/143333
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.